Press Releases

 
Press Releases
Date Title and Summary View
Oct 9, 2013 SALT LAKE CITY, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data showing the high prevalence and overlap between hereditary colon cancer and hereditary breast and ovarian cancer in patients previously diagnosed with endometrial and ovarian cancer. Myriad is presenting this data and another he...
Oct 7, 2013 SALT LAKE CITY, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent increase in mutations detected in cancer predisposition genes in patients with a prior history of colon cancer and/or polyps. M...
Oct 1, 2013 SALT LAKE CITY, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that BioMarin Pharmaceutical Inc. will use Myriad's BRACAnalysis® test in connection with its pivotal Phase 3 clinical studies for BMN 673. BMN 673 is a novel, orally-active PARP inhibitor designed to induce synthetic lethality in BRCA-deficien...
Sep 25, 2013 SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in patients with early-stage, resectable lung adenocarcinoma and may be a valuable tool for selecting which earl...
Sep 5, 2013 SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President of Myriad Genetic Laboratories, Inc. is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 2:55 p.m. Eastern on September 10, 2013 in New York City. The presentation will be available to ...
Sep 5, 2013 SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has launched myRisk Hereditary Cancer, a new multi-gene diagnostic test that will provide increased sensitivity by analyzing 25 genes associated with eight major cancers including: breast, colorectal, ovarian, endometrial, pancreatic, prost...
Sep 4, 2013 SALT LAKE CITY, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into an expanded, nonexclusive global collaboration agreement with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program. Olaparib is an investigational orally active poly-ADP ribose ...
Aug 13, 2013 SALT LAKE CITY, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal fourth quarter and full fiscal year ended June 30, 2013. Revenue for the fiscal fourth quarter increased 31 percent over the same period in the prior year to $174.1 million. Fiscal fourth quarter earnings per dilute...
Jul 30, 2013 SALT LAKE CITY, July 30, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will hold its fourth-quarter 2013 sales and earnings conference call with institutional investors and analysts at 4:30 p.m. ET on Tuesday, Aug. 13. During the call, Peter D. Meldrum, president and chief executive officer; James Evans, chief fina...
Jul 15, 2013 SALT LAKE CITY, July 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced a program to provide financial assistance to underinsured patients. Beginning July 22, Myriad will offer financial assistance to reduce qualified underinsured patients' out-of-pocket cost to no more than $375. To be eligible, patients must have pri...
Page: FirstPrevious ...
9
... NextLast
= add release to Briefcase